Quest Diagnostics DGX Q2 2026: 10.5% EPS Beat on Surging Test Volume
As seen on the 24/7 Wall St. homepage on July 23, 2026.
Quest Diagnostics crushed Q2 earnings with a 10.5% EPS beat fueled by a 13.1% surge in testing volume, lifting the company's full-year guidance on broad momentum in Alzheimer's blood tests and cancer diagnostics.
Continue ReadingShow less
Quest Diagnostics reported Q2 2026 earnings per share of $3.12, well ahead of the $2.82 consensus estimate and representing the largest beat in at least the past eight quarters. Revenue came in at $3.04 billion, topping estimates by about 2.4%. The standout driver was a 13.1% surge in testing volume, a meaningful acceleration that signals broad-based demand across the company's diagnostic menu rather than a one-time lift.
Two growth areas in particular gave the quarter its momentum: Alzheimer's blood tests and cancer diagnostics. Both categories have been expanding as clinicians increasingly lean on lab-based screening tools, and Quest appears to be capturing that shift at scale. The strength was substantial enough that management raised its full-year guidance, suggesting the volume gains are expected to carry into the back half of 2026.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
Zooming out, the Q2 result continues a consistent pattern of modest beats across recent quarters — Q1 2026 came in at $2.50 versus a $2.37 estimate, and Q2 2025 printed $2.62 against a $2.57 forecast — but the magnitude of this quarter's outperformance stands apart. Investors will be watching whether the testing-volume tailwind holds and whether Alzheimer's and oncology diagnostics can sustain their momentum through the remainder of the year.
Mentioned: DGX